Acetylon Pharmaceuticals
Seaport Center
70 Fargo Street, Suite 205
Boston
Massachusetts
02210
United States
Tel: 617-245-1300
Fax: 617-245-1301
Website: http://www.acetylon.com/
Email: info@acetylon.com
53 articles about Acetylon Pharmaceuticals
-
Boston's Acetylon Gets Taken Out By Celgene, Will Spin Out Startup Regenacy Pharma
12/6/2016
-
Acetylon Presents Preclinical Data Demonstrating The Utility Of Selective HDAC1,2 Inhibition By ACY-957 To Induce Gamma Globin (HBG) Protein Expression For The Treatment Of Sickle Cell Disease And Beta-Thalassemia
12/5/2016
-
Acetylon Presents Early Phase 1a/1b Results For Citarinostat (ACY-241) In Combination With Pomalyst And Dexamethasone Showing Promising Treatment Responses In Relapsed Or Relapsed-And-Refractory Multiple Myeloma
12/5/2016
-
Acetylon Announces Upcoming Scientific Presentations On The Use Of Selective HDAC Inhibitors In Treating Genetic Blood Disorders And Cancers
12/2/2016
-
Celgene Passes on Option-to-Buy $600 Million Deal for Boston's Acetylon
8/8/2016
-
Acetylon Pharmaceuticals Presents Data On The Use Of HDAC6 Inhibitors Ricolinostat (ACY-1215) And ACY-241 In Combination With Pomalidomide And Dexamethasone For The Treatment Of Multiple Myeloma
6/13/2016
-
ASCO2016: Acetylon Pharmaceuticals Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties Of Ricolinostat In Preclinical Melanoma Models
6/3/2016
-
Acetylon Pharmaceuticals Publishes New Mechanism For The Treatment Of Sickle Cell Disease/Beta-Thalassemia With Selective HDAC1/2 Inhibition In Plos One
5/4/2016
-
Acetylon Pharmaceuticals Announces The Presentation Of Preclinical Data At AACR Supporting The Use Of Selective HDAC6 Inhibition To Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology
4/20/2016
-
Acetylon Pharmaceuticals Presents Data On The Use Of HDAC 6 Inhibitors Ricolinostat (ACY-1215) And ACY-241 In Combination With Pomalidomide For The Treatment Of Multiple Myeloma
12/7/2015
-
Acetylon Pharmaceuticals Presents Data On The Pharmacokinetics And Hbe/Hbg Hemoglobin Induction Following Once Daily Dosing Of An Oral HDAC1,2 Inhibitor In Animal Models
12/7/2015
-
Acetylon Pharmaceuticals Presents Data From Three Phase Ib Studies Of Ricolinostat (ACY-1215) For The Treatment Of Lymphoma And Multiple Myeloma
12/7/2015
-
Acetylon Pharmaceuticals’s Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-Tumor Activity Of Paclitaxel In Preclinical Solid Tumor Models
11/6/2015
-
Acetylon Pharmaceuticals To Present At BioPharm America 2015
9/14/2015
-
Acetylon Pharmaceuticals Presented Positive Preliminary Data From Phase 1b/2 Trial Of Ricolinostat In Combination With Pomalyst As Potential Oral Treatment For Patients With Multiple Myeloma
6/16/2015
-
Acetylon Pharmaceuticals Presents Data On Synergistic Activity Of Selective HDAC6 Inhibition In Preclinical Models Of Multiple Myeloma And Mantle Cell Lymphoma At The AACR Annual Meeting
4/22/2015
-
Acetylon Pharmaceuticals Announces Preclinical Anti-Cancer Activity Of Selective HDAC1/2 Inhibitors In Neuroblastoma And Acute Myeloid Leukemia
4/20/2015
-
Acetylon Pharmaceuticals Presents At The Wells Fargo Celgene Partnership Forum
1/22/2015
-
Acetylon Pharmaceuticals Presents Positive Preclinical Data On Selective HDAC1/2 Inhibition For The Treatment Of Sickle Cell Disease/?-Thalassemia
12/9/2014
-
Acetylon Pharmaceuticals Announces Ricolinostat Continues To Demonstrate Clinically Meaningful And Durable Disease Response Rates In Phase 1b Combination Studies In Multiple Myeloma
12/9/2014